The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Global Tuberculosis Control 2011, WHO Report 2011
Behera, D. (2012) · The Indian Journal of Medical Research · Cited by 1,022
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
Self-citationAn Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 912
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. A. M., & Dekhuijzen, R. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 781
Newsom, S. W. B. (2006) · Journal of Hospital Infection · doi:10.1016/j.jhin.2006.06.003 · Cited by 635
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998
Joint Tuberculosis Committee of the British Thoracic Society (1998) · Thorax · doi:10.1136/thx.53.7.536 · Cited by 527
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Peloquin, C. A. (2002) · Drugs · doi:10.2165/00003495-200262150-00001 · Cited by 446
Toxic Hepatitis with Isoniazid and Rifampin
Steele, M. A., Burk, R. F., & DesPrez, R. M. (1991) · Chest · doi:10.1378/chest.99.2.465 · Cited by 437
BLUM, M., GRANT, D. M., McBRIDE, W., HEIM, M., & MEYER, U. A. (1990) · DNA and Cell Biology · doi:10.1089/dna.1990.9.193 · Cited by 435
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432
Effect of age and gender on the activity of human hepatic CYP3A
Hunt, C. M., Westerkam, W. R., & Stave, G. M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90010-g · Cited by 426
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D. (2003) · Hepatology · doi:10.1053/jhep.2003.50144 · Cited by 426
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
Schaberg, T., Rebhan, K., & Lode, H. (1996) · European Respiratory Journal · doi:10.1183/09031936.96.09102026 · Cited by 379
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Nolan, C. M., Goldberg, S. V., & Buskin, S. E. (1999) · JAMA · doi:10.1001/jama.281.11.1014 · Cited by 368
Byrne, J. A., Strautnieks, S. S., Mieli–Vergani, G., Higgins, C. F., Linton, K. J., & Thompson, R. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36591 · Cited by 337
Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., & Mehra, N. K. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2108091 · Cited by 336
Idiosyncratic drug reactions: the reactive metabolite syndromes
Knowles, S. R., Uetrecht, J., & Shear, N. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03137-8 · Cited by 331
Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver
Larrey, D. (2002) · Seminars in Liver Disease · doi:10.1055/s-2002-30101 · Cited by 320
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9711039 · Cited by 292
Acharya, S. K., Dasarathy, S., Kumer, T. L., Sushma, S., Prasanna, K. S., Tandon, A., Sreenivas, V, Nijhawan, S., Panda, S. K., Nanda, S. K., et al. (1996) · Hepatology · doi:10.1002/hep.510230622 · Cited by 262
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
Pande, J. N., Singh, S. P., Khilnani, G. C., Khilnani, S., & Tandon, R. K. (1996) · Thorax · doi:10.1136/thx.51.2.132 · Cited by 244
(1982) · Europe PMC (PubMed Central) · Cited by 236
Mitochondrial abnormalities—A link to idiosyncratic drug hepatotoxicity?
Boelsterli, U. A., & Lim, P. L. K. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.013 · Cited by 232
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4.
Hustert, E., Zibat, A., Presecan, E., Eiselt, R., Mueller, R., Fuss, C., Brehm, I., Brinkmann, U., Eichelbaum, M. F., Wojnowski, L., et al. (2001) · PubMed · Cited by 218
Grosset, J., & Leventis, S. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s440 · Cited by 218
Hepatic safety of antibiotics used in primary care
Andrade, R. J., & Tulkens, P. M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr159 · Cited by 213
Huang, Y.-S., Su, W.-J., Huang, Y.-H., Chen, C.-Y., Chang, F.-Y., Lin, H.-C., & Lee, S.-D. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.009 · Cited by 212
Influence of Diet and Nutritional Status on Drug Metabolism
Walter-Sack, I., & Klotz, U. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631010-00004 · Cited by 209
Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E., Chrisman, C. R., & Self, T. H. (2005) · Chest · doi:10.1378/chest.128.1.116 · Cited by 209
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202
Isoniazid-associated Hepatitis Deaths: A Review of Available Information
Snider, D. E., & Caras, G. J. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.2_pt_1.494 · Cited by 199
Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U. M., & Wojnowski, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404949200 · Cited by 198
Kumar, R., Shalimar, Bhatia, V., Khanal, S., Sreenivas, V., Gupta, D. S., Panda, S. K., & Acharya, S. K. (2010) · Hepatology · doi:10.1002/hep.23534 · Cited by 193
A Fresh Look at the Mechanism of Isoniazid-Induced Hepatotoxicity
Metushi, I. G., Cai, P., Zhu, X., Nakagawa, T., & Uetrecht, J. P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.355 · Cited by 190
Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., & Majumder, P. P. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02585.x · Cited by 187
Menzies, D., Dion, M.-J., Rabinovitch, B., Mannix, S., Brassard, P., & Schwartzman, K. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-478oc · Cited by 168
The danger hypothesis—potential role in idiosyncratic drug reactions
Pirmohamed, M., Naisbitt, D. J., Gordon, F., & Park, B. K. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00255-x · Cited by 164
Sharma, S. K., Singla, R., Sarda, P., Mohan, A., Makharia, G. K., Jayaswal, A., Sreenivas, V., & Singh, S. (2010) · Clinical Infectious Diseases · doi:10.1086/650576 · Cited by 159
Frequency and type of reactions to antituberculosis drugs: Observations in routine treatment
Ormerod, L. P., & Horsfield, N. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90073-8 · Cited by 158
Liver injury during antituberculosis treatment: An 11-year study
Døssing, M., Wilcke, J. T., Askgaard, D. S., & Nybo, B. (1996) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(96)90098-2 · Cited by 157
Serum Transaminase Elevations and Other Hepatic Abnormalities in Patients Receiving Isoniazid
Scharer, L. L. M. D., & SMITH, J. P. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-6-1113 · Cited by 155
Isoniazid – and rifampicin–induced oxidative hepatic injury – protection by N–acetylcysteine
Attri, S. V., Rana, S. V., Vaiphei, K., Sodhi, C. P., Katyal, R., Goel, R. C., Nain, C. K., & Singh, K. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700674230830 · Cited by 148
Martínez, E., Collazos, J., & Mayo, J. (1999) · Medicine · doi:10.1097/00005792-199911000-00001 · Cited by 135
Nakajima, A., Fukami, T., Kobayashi, Y., Watanabe, A., Nakajima, M., & Yokoi, T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.003 · Cited by 134
Hein, D. W., Doll, M. A., Rustan, T. D., & Ferguson, R. J. (1995) · PubMed · Cited by 130
Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
Singla, R., Sharma, S. K., Mohan, A., Makharia, G. K., Sreenivas, V., Jha, B. K., Kumar, S., Sarda, P., & Singh, S. (2010) · PubMed · Cited by 126
The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.
Fernández‐Villar, A., SOPEÑA, B., Fernández-Villar, J., Vázquez-Gallardo, R., Ulloa, F., Leiro, V., Mosteiro, M., & Piñeiro, L. (2004) · PubMed · Cited by 126
Papastavros, T., Dolovich, L. R., Holbrook, A. M., et al. (2002) · PubMed · Cited by 126
Incidence of Hepatotoxicity Due to Antitubercular Medicines and Assessment of Risk Factors
Shakya, R., Rao, B. S., & Shrestha, B. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1d525 · Cited by 123
The management of anti-tuberculosis drug-induced hepatotoxicity.
Tahaoğlu, K., Ataç, G., Sevim, T., Tärün, T., Yazıcıoğlu, Ö. M., Horzum, G., Gemci, I., Ongel, A., Kapaklı, N., & Aksoy, E. (2001) · PubMed · Cited by 123
Yimer, G., Ueda, N., Habtewold, A., Amogne, W., Suda, A., Riedel, K., Burhenne, J., Aderaye, G., Lindquist, L., Makonnen, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027810 · Cited by 122
Joint, T. (1998) · PubMed · Cited by 118
Sarma, G. R., Immanuel, C., Kailasam, S., Narayana, A. S. L., & Venkatesan, P. (1986) · PubMed · doi:10.1164/arrd.1986.133.6.1072 · Cited by 116
Rifampicin-induced acute renal failure: a series of 60 patients
Covic, A. C., Goldsmith, D. J. A., Segall, L., Stoicescu, C. I., Lungu, S., Volovăţ, C., & Covic, M. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.4.924 · Cited by 116
Wang, P. F., Xie, S.-Y., Hao, Q., Zhang, C., & Jiang, B.-F. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.11.0377 · Cited by 116
Leiro, V., Fernández‐Villar, A., Valverde, D., Constenla, L., Vázquez, R., Piñeiro, L., & González‐Quintela, A. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01700.x · Cited by 115
Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore.
Teleman, M. D., Chee, C. B. E., Earnest, A., & Wang, Y. T. (2002) · PubMed · Cited by 111
Prevention of hepatotoxicity due to anti tuberculosis treatment: A novel integrative approach
Adhvaryu, M., Reddy, N. M., & Vakharia, B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4753 · Cited by 109
Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity
Baniasadi, S., Eftekhari, P., Tabarsi, P., Fahimi, F., Raoufy, M. R., Masjedi, M. R., & Velayati, A. A. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32833aa11b · Cited by 106
Overview of fluoroquinolone safety
Wolfson, J. S., & Hooper, D. C. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90330-z · Cited by 98
Bose, P. D., Sarma, M. P., Medhi, S., Das, B. C., Husain, S. A., & Kar, P. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06355.x · Cited by 97
Ziakas, P. D., & Mylonakis, E. E. (2009) · Clinical Infectious Diseases · doi:10.1086/647944 · Cited by 96
Hwang, S., WU, J., LEE, C., Yen, F., Lu, C., LIN, T., & LEE, S. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00353.x · Cited by 91
Absorption, metabolism and excretion of pyrazinamide in man
Ellard, G. A. (1969) · Tubercle · doi:10.1016/0041-3879(69)90020-8 · Cited by 90
Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load
Wang, J., Liu, C., Hu, F., Chang, H.-C., Liu, J.-L., Chen, J., Yu, C., Lee, L., Kao, J., & Yang, P. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.04.005 · Cited by 88
Lee, A. M., Mennone, J. Z., Jones, R. C., et al. (2002) · PubMed · Cited by 77
Genetic variants in antioxidant pathway: Risk factors for hepatotoxicity in tuberculosis patients
Nanashima, K., Mawatari, T., Tahara, N., Higuchi, N., Nakaura, A., Inamine, T., Kondo, S., Yanagihara, K., Fukushima, K., Suyama, N., et al. (2012) · Tuberculosis · doi:10.1016/j.tube.2011.12.004 · Cited by 71
Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity
Aithal, G. P. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.519 · Cited by 69
Self-citationSevere hepatotoxicity due to anti-tuberculosis drugs in Spain.
Tost, J. R., Vidal, R., Caylà, J. A., Diaz-Cabanela, D., Jiménez, A., & Broquetas, J. M. (2005) · PubMed · Cited by 66
Pirmohamed, M., Aithal, G. P., Behr, E. R., Daly, A. K., & Roden, D. M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.30 · Cited by 66
Self-citationTherapeutic drug monitoring in the treatment of tuberculosis patients
Magis-Escurra, C., van den Boogaard, J., IJdema, D., Boeree, M. J., & Aarnoutse, R. E. (2011) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2011.12.001 · Cited by 63
Saigal, S., Agarwal, S. R., Nandeesh, H. P., & Sarin, S. K. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02570.x · Cited by 62
Nannelli, A., Chirulli, V., Longo, V. G., et al. (2008) · Toxicology · doi:10.1016/j.tox.2008.08.004 · Cited by 58
Latest Industry Information on the Safety Profile of Levofloxacin in the US
Kahn, J. B. (2001) · Chemotherapy · doi:10.1159/000057842 · Cited by 58
Safety of Fluoroquinolone Use in Patients with Hepatotoxicity Induced by Anti‐Tuberculosis Regimens
Ho, C., Chen, Y., Hu, F., Yu, C., Yang, P., & Luh, K. (2009) · Clinical Infectious Diseases · doi:10.1086/598929 · Cited by 49
Factors That Complicate the Treatment of Tuberculosis in HIV-Infected Patients
Dworkin, M. S., Adams, M. R., Cohn, D. L., Davidson, A. J., Buskin, S. E., Horwitch, C., Morse, A., Sackoff, J., Thompson, M., Wotring, L. L., et al. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000152400.36723.85 · Cited by 42
Antituberculosis therapy drug‐induced liver injury and acute liver failure†
Devarbhavi, H. C., Dierkhising, R., & Kremers, W. K. (2010) · Hepatology · doi:10.1002/hep.23805 · Cited by 41
Hunt, C. M. (2010) · Hepatology · doi:10.1002/hep.24022 · Cited by 39
Rifampin Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection
Fountain, F. F., Tolley, E. A., Jacobs, A. R., & Self, T. H. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31818c0134 · Cited by 38
Possible Gatifloxacin-Induced Fulminant Hepatic Failure
Coleman, C. I., Spencer, J. V., Chung, J., & Reddy, P. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a414 · Cited by 37
LoBue, P. A., & Ks, M. (2005) · PubMed · Cited by 35
Murata, K., HAMADA, M., Sugimoto, K., & Nakano, T. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.09.017 · Cited by 30
Isoniazid vs. Rifampin for Latent Tuberculosis Infection in Jail Inmates: Toxicity and Adherence
White, M. C., Tulsky, J. P., Lee, J. R.-J., Chen, L., Goldenson, J., Spetz, J., & Kawamura, L. M. (2012) · Journal of Correctional Health Care · doi:10.1177/1078345811435973 · Cited by 29
Preempting and preventing drug-induced liver injury
Aithal, G. P., & Daly, A. K. (2010) · Nature Genetics · doi:10.1038/ng0810-650 · Cited by 28
Self-citationPyrazinamide-Induced Granulomatous Hepatitis
Knobel, B., Buyanowsky, G., Dan, M., & Zaidel, L. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199706000-00019 · Cited by 27
Facino, R. M., & Carini, M. (1980) · Pharmacological Research Communications · doi:10.1016/s0031-6989(80)80138-x · Cited by 14
Cited by
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
LeFort, K. R., Rungratanawanich, W., & Song, B.-J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05061-7 · Cited by 202
Drug-induced liver injury in older people
Lucena, M. I., Sanabria, J., García-Cortes, M., Stephens, C., & Andrade, R. J. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30006-6 · Cited by 77
Nicoletti, P., Devarbhavi, H., Goel, A., Venkatesan, R., Eapen, C. E., Grove, J. I., Zafer, S., Bjornsson, E., Lucena, M. I., Andrade, R. J., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2100 · Cited by 61
Self-citationNiu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105404 · Cited by 58
Self-citation
Metadata
- Authors
- Ramappa, V., & Aithal, G. P.
- Venue
- Journal of Clinical and Experimental Hepatology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 3
- Issue
- 1
- Pages
- 37-49
- ISSN
- 0973-6883 (ISSN-L)
- OpenAlex
- W2001811916
- Cited by
- 508
- References
- 98
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.